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Background. Human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) are defined according to 
their diagnostic degrees as follows: asymptomatic neurocognitive impairment, mild neurocognitive disorder, and HIV-associated 
dementia. Because high adherence to combined antiretroviral therapy (cART) is required to maintain viral suppression among 
HIV-infected patients, it is important to investigate the impact of HAND on medication adherence. Our study hypothesis was that 
patients with HAND had a lower medication adherence than patients who did not have HAND.
Methods. This was an observational, exploratory, 2-center pilot study of patients who had a state-of-the-art neurocognitive 
assessment performed between January 2011 and June 2015 while also being followed at their respective adherence clinics. Adherence 
was measured with electronic monitors. Patients’ sociodemographic characteristics, HIV viral load, and CD4 counts were retrieved 
from the Swiss HIV Cohort Study database. At each time t, adherence was computed as the proportion of patients taking medication 
as prescribed at that time.
Results. We included 59 patients, with a median (Q1, Q3) age of 53 years (47–58) and 39 (66%) were male participants. Twenty-
two patients (35%) had no neurocognitive deficits, 16 (27%) patients had HAND, and 21 (35%) patients had non-HAND (mostly 
depression). Implementation over 3 years showed a significant decline (50%) in medication adherence among patients diagnosed 
with HAND in comparison with patients who had a normal neuropsychological status or a non-HIV-related cognitive deficit (imple-
mentation stayed 90% during follow-up).
Conclusions. Our findings support the hypothesis that HAND is associated with reduced cART adherence.
Keywords. HIV; HIV-associated neurocognitive disorders; medication adherence.
 
People living with human immunodeficiency virus (HIV) 
remain vulnerable to neurocognitive disorders (NCDs) despite 
an undetectable HIV viral load [1]. Human immunodeficiency 
virus-associated NCDs (HAND) are defined according to their 
severity as follows: asymptomatic neurocognitive impair-
ment (ANI), mild NCD (MND), and HIV-associated demen-
tia (HAD) [2]. Despite the significant decline in the incidence 
of HAD due to the introduction of combined antiretroviral 
therapy (cART), the prevalence of ANI and MND has increased 
by 30%–50% [3–5]. The neuropathogenesis of HAND remains 
unclear, although several factors such as the HIV infection itself 
[6], cART toxicity [7], and aging [8] are possible explanations.
Medication adherence is generally defined as the extent to 
which patients follow their medication regimen as prescribed 
by their healthcare providers [9]. It has 3 phases: initiation, 
which marks the start of treatment; implementation, which 
marks the extent to which the patient follows the dosing reg-
imen; and discontinuation, which marks the interruption of 
treatment [9]. Nonadherence can occur in any of those phases, 
including premature interruption of treatment, defined as non-
persistence, or suboptimal implementation [10, 11]. There are 
several ways of monitoring medication adherence including 
pill counts, patient self-reports, and electronic monitors (EMs), 
which is the gold standard [9]. Nonadherence to antiretro-
viral (ARV) treatment is associated with virologic failure, the 
development of drug-resistant mutations, and a higher risk of 
mortality [12–14]. Therefore, a better understanding of the pre-
dictors of poor adherence is needed.
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To date, few studies cross-sectional in nature have used sen-
sitive measures of medication adherence and neurocognitive 
function testing to investigate the association between HAND 
and cART adherence [15–18]. Nonetheless, using electroni-
cally measured medication adherence over 6  months, Becker 
et  al [19] revealed longitudinal changes in neurocognitive 
function in the areas of attention and working memory, speed 
of information processing, learning and memory, verbal flu-
ency, executive functioning, and motor speed. Our goal is to 
describe medication adherence longitudinally using EMs data 
for HIV patients on whom neurocognitive assessment testing 
was performed at university hospitals in Lausanne and Bern in 
Switzerland. Our study hypothesis is that there is an association 
between a HAND diagnosis and medication adherence.
METHODS
Data Sources
The Swiss HIV Cohort Study (SHCS), an ongoing multicenter 
prospective observational study for interdisciplinary HIV-
related research, includes 69% of all HIV-positive patients 
in Switzerland [20]. All sociodemographic and clinical lab-
oratory variables were extracted from the SHCS database on 
the date of neurocognitive assessment or within a range of 
2–3 months before for data that were not available on the exact 
date (eg, laboratory results). To identify patients having neu-
rocognitive assessments, we referred to 2 research databases: 
one is from a multidisciplinary (infectious diseases specialist, 
neuropsychologist, neurologist, psychiatrist and radiologist) 
Neuro-HIV outpatient clinic that was established in 2011 [21] 
of patients with cognitive complaints that can result in alter-
ations in memory, attention, and reasoning; the other is from 
the Neurocognitive Assessment in the Metabolic and Aging 
Cohort (NAMACO) study (nested within the SHCS), which 
began in 2013 and included HIV patients aged 45  years and 
older, with or without neurocognitive complaints, who pre-
sented for a neuropsychological exam, bone densitometry, and 
metabolic assessment every 2  years for 4  years [22]. Because 
the neurocognitive assessment testing began in 2011, we had 
1 test result per patient available, which did not allow for eval-
uating the temporal causality between longitudinal adherence 
and NCDs. However, we assume that NCDs mostly occurred in 
patients before detection by neurocognitive testing. Due to the 
small number of patients relative to neurocognitive category, 
we could not evaluate adherence relative to neurocognitive 
category. Instead, we evaluated only the presence of a HAND 
diagnosis.
A medication adherence support program exists at the com-
munity pharmacy of the Department of Ambulatory Care and 
Community Medicine, University of Lausanne, in collaboration 
with the Infectious Diseases Service of the University Hospital. 
Medication adherence to each ARV drug is monitored via 
EMs (MEMS; Aardex MWV Healthcare, Sion, Switzerland), 
combined with manual pill counts, and motivational interviews. 
Electronic adherence data are shown to the patient as feedback, 
and a report is issued to the physician after each interview [23]. 
Patients initiating their cART, or patients with adherence diffi-
culties anytime during their therapeutic pathway, are referred 
to this program by their Infectious Diseases physician. In Bern, 
the medication adherence intervention is performed at the 
Infectious Disease Service at the University Hospital and deliv-
ered by a nurse. All patients have only 1 component of their 
cART monitored electronically for a period of 3 months at the 
beginning of follow up. Some patients with adherence difficul-
ties are again included in the program after the initial period.
Selection of Study Participants
In 2016, we cross-checked 5 databases to identify partici-
pants: the databases of the adherence program in Lausanne 
and Bern, the SHCS database, both databases of the Neuro-
HIV multidisciplinary outpatient clinic, and the NAMACO 
study. We included all patients with electronically monitored 
adherence data and who were found either in the Neuro-HIV 
multidisciplinary outpatient clinic or the NAMACO databases. 
Longitudinal electronic measurements of adherence to ARV 
were assessed from 2008 to 2015, before neurocognitive assess-
ment in all patients, except for 2 who were assessed before the 
initiation of electronic adherence monitoring. All participants 
were on cART.
Measures and Data Collection
The standardized neuropsychological assessment, inspired by 
the international START study [24], covers 7 cognitive domains: 
memory, attention, speed of information processing, execu-
tive functions, language, motor skills, and sensory-perceptive 
abilities. The neuropsychological test series used in this study 
consists of 9 tests that provide both quantitative and qualita-
tive measures for a range of cognitive abilities. The tests are as 
follows: Hopkins Verbal Learning Test-Revised, Color Trails 1 
and 2, WAIS-IV Digit Symbol Test, Five-point Figural Fluency 
Test, WAIS-IV Digit Spans Forward and Backward, Grooved 
Pegboard Tests, Finger Tapping Test, Victoria Stroop Test, and 
Semantic Verbal Fluency Test. Scales rating mood (CES-D) 
and daily life functioning (IADL including subscales from the 
PAOFI questionnaire) were also administered. During the visit 
to the Neuro-HIV multidisciplinary outpatient clinic with a 
trained neuropsychologist, neuropsychological evaluation was 
individually adapted in terms of cognitive and behavioral com-
plaints, age, and socioeducational level. Each individual visit 
to the Neuro-HIV multidisciplinary outpatient clinic lasted 2 
hours or more.
Medication adherence was measured using EMs (MEMS; 
Aardex MWV Healthcare) that use a pressure-activated micro-
processor in the medication pill box that automatically records 
the date and time of each opening per single ARV drug. The key 
measures in the EM data system include patient identification 
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(ID), EM monitor ID, drug name, prescribed doses per day, the 
opening event day and time, and the start and stop dates of the 
monitoring period. Data were retrieved from the monitor using 
a specially designed communication module connected to a 
password-protected computer at the University Community 
Pharmacy in Lausanne and at the university hospital in Bern. 
Patients regularly visited the pharmacy (at least once per tri-
mester), during which time they were asked whether they had 
periods of pocket dosing (ie, taking out medication for later 
use), whether they missed doses (and whether it was voluntary 
or involuntary), or whether they had nonmonitored periods 
(NMPs) due to hospitalization. In addition, pharmacists per-
formed a manual pill count of the number of pills remaining in 
the pillbox since the patient’s last visit. The pill count informa-
tion allowed us to reconcile the EM data by comparing the val-
ues of electronic adherence as recorded by EMs to adherence as 
calculated by the pill count. This was not performed for the data 
in Bern because the intervention does not involve a pill count. 
However, because patients in Bern are followed for a shorter 
duration, very little discrepancy in electronically monitored 
adherence was found. Patients at the Lausanne and Bern centers 
were not blinded to using EMs because the monitors were used 
routinely in the respective medication adherence programs.
Reconciliation of Electronic Monitors Raw Data With Pill Count
Electronic monitor raw data were extracted using Medamigo 
software (AARDEX Ltd, Sion, Switzerland) where percentage 
of adherence was calculated as the number of openings/doses 
recorded by EMs over the number of prescribed doses/expected 
openings for a specific time period. This period is defined as the 
number of days elapsed between 2 consecutive patient visits at 
the pharmacy, ie, an intervisit patient phase. Overall adherence 
was calculated as the average adherence for all drugs taken. In 
the Lausanne center, periods of nonsystematic use of EMs, such 
as NMPs and periods of pocket dosing, were identified by the 
EMs patient visit report, and adherence based on EM data was 
then compared with that based on pill count data. We calculated 
the absolute difference between electronic adherence, as meas-
ured using EMs (I), and pill count (J) using the formula: (ABS(J-
I)/J) × 100. If the difference between pill count and electronic 
adherence was more than 25%, periods of nonmonitoring and 
pocket dosing, as described by the patients before reviewing the 
EMs results and notification from the pharmacist in the patient 
visit report, were identified and the electronic adherence calcu-
lation was adjusted accordingly. If the difference was still more 
than 25% or periods of pocket dosing could not be identified, 
these were considered as missing values because EM measure-
ments were not sufficiently reliable for research purposes.
We decided to use a 25% cutoff because we believed that a 
difference above that threshold was considered substantial. 
A “day” was defined as the 24-hour period from 3:00 am to 2:59 
am for all participants to allow for those who took their ARV 
medication late at night. All excess EM openings (more than the 
number of prescribed doses/openings) were ignored. Phases in 
which EMs could not be read or analyzed due to technical rea-
sons (such as when patients forgot to bring their EMs to visits 
or NMPs that could not be reconciled based on the visit reports) 
were excluded from the analysis and considered as missing val-
ues. Because patients used 1 EM per ARV drug, if only 1 EM 
of 2 or 3 was valid, analysis of the phase was completed using 
the valid data only. We performed a sensitivity analysis with the 
discarded data after reconciliation and compared both results.
Data Analysis
Demographic and clinical characteristics were compared 
between different cognitive groups using the χ2 test, Fisher’s 
exact test, Kruskal-Wallis test, or analysis of variance (followed 
by a post hoc test if necessary) where appropriate. Significance 
was set at a P value of less than .05 for all statistics. Variables 
included in the descriptive analysis were age, sex, education, 
ethnicity, sexual orientation, HIV transmission group, fol-
low-up duration with EMs, treatment duration, HIV viral load, 
nadir CD4 count, and CD4 count at the time of neurocognitive 
assessment.
Repeated binary measures were available for daily EM infor-
mation throughout the entire follow-up period that stated 
whether a patient took at least the prescribed dose of medication 
on any day d. On each day d, implementation, the operational 
definition of adherence in this study, was computed as the pro-
portion of patients who took at least the prescribed dose at that 
time [9]. However, for clarity, we herein use the word “adher-
ence”, which strictly refers to implementation. Adherence was 
evaluated for each of the 3 groups of patients: normal (absence 
of NCDs), HIV-associated disorders, and non-HIV-associ-
ated disorders. Generalized estimated equations (GEE) were 
adopted to model adherence over time. For sufficient number 
of patients in each group at each date, analyses were truncated 
to 3 years, starting from the beginning of individual follow-up. 
The GEE models represent an extension of the logistic model, 
considering the possible dependence between repeated binary 
measures in the same individual. These models are based on 
correlation matrices that represent mean dependency between 
individual measurements, providing a robust estimation of the 
population mean response (adherence).
Adherence was modeled both globally and according to the 
neurocognitive group. In this case, the group variable was intro-
duced into the model both alone, measuring the group effect 
at baseline, and with an interaction with time, measuring the 
effect of neurocognitive diagnosis on the adherence pattern 
over time. The latter was expressed by different powers of the 
time variable (polynomial model), retaining only significant 
time effects and interactions in the model (P < .05). The same 
statistical approach was adopted to estimate the probability of 
detectable ribonucleic acid (RNA) over time (RNA level above 
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20 copies/mL) according to the neurocognitive diagnosis. All 
analyses were completed using the R statistical package, version 
3.1 (R: A language and environment for statistical computing; 
R Foundation for Statistical Computing, Vienna, Austria [URL: 
http://www.R-project.org]).
Ethics
All patients who are involved in the SHCS, Neuro-HIV multi-
disciplinary outpatient clinic, or the NAMACO study have pro-
vided written consent to use their data for each of the research 
projects. The research proposal to use electronic medication 
adherence data was approved by the Ethics committees of 
the cantons Vaud and Bern in Switzerland, protocol number 
PB_2016-02022 (72/15) on August 29, 2016.
RESULTS
Descriptive Statistics
We included 59 patients: 42 from Lausanne and 17 from Bern. 
At the time of neurocognitive assessment, as shown in Table 1, 
the median (Q1, Q3) CD4 count was 603 (486−735) cells/µL; 
the median (Q1, Q3) age was 53 (47−58) years, and 39 subjects 
(66%) were male. Of 59 patients, 22 (35%) had no neurocogni-
tive deficit, 16 (27%) had HAND (9 ANI, 4 MND, and 3 HAD), 
and 21 (35%) had non-HIV-related NCDs. Non-HANDs were 
attributed to other confounding factors such as psychiatric dis-
orders (mild to severe depression, anxiety), substance abuse 
(alcohol, illicit drug or cannabis use), and cerebrovascular or 
neurodegenerative diseases. The median duration of follow 
up in the adherence program was 2.3  years, and the median 
time between the start of follow up in the adherence program 
and the date of neurocognitive assessment was 3.42 years. All 
patients received neurocognitive assessments during follow 
up in the medication adherence program, except for 2 who 
received their neurocognitive assessments before being fol-
lowed in the adherence program. Participant groups were sig-
nificantly different in terms of race/ethnicity, education, sexual 
orientation, duration since starting treatment, and source of 
HIV transmission.
Reconciliation of Electronic Monitors Data
The analysis of EMs adherence data yielded 2606 intervisit 
patient phases over a median of 858  days (2.3  years) of daily 
electronic measurements, which corresponds to 65 127 EM 
openings in total. Validation of the electronic EMs data from 
the Lausanne center showed that 35 patients over 367 phases 
had a difference of more than 25% between the 2 measures 
of adherence used, pill count, and electronic measurement by 
EMs, for a minimum of 1 patient phase. Over 91 phases for 24 
Table 1. Patient Sociodemographic and Clinical Characteristics
Characteristics All Patients n = 59
Absence of NC  
Disorders n = 22 HAND n = 16 Non-HAND n = 21 P Value
Age median (Q1, Q3) 53 (47, 58) 53.3 (48, 57) 51 (47, 57) 50 (42, 58) .248
Gender
Male 39 (66%) 17 (77%) 9 (56%) 13 (62%) .351
Ethnicity
White 44 (75%) 21 (95.4%) 10 (63%) 13 (62%) .011
Sexual Orientation
Heterosexual 41 (69%) 2 (20%) 10 (76%) 16 (76%) .192
Source of HIV Contamination
Heterosexual transmission 23 (39%) 3 (13.6%) 10 (62.5%) 10 (47.6%) .006
Education
Less than a bachelor’s degree 44 (75%) 11 (50%) 15 (38%) 18 (86%) .001
CD4 nadir 205 (119–261) 208 (131–347) 177 (106–219) 208 (91–253) .613
CD4 cell count/μL, median (IQR) at inclusion in the  
adherence program
409 (242–535) 409 (219–504) 487 (278–638) 357 (275–489) .417
HIV-RNA copies/mL, median (IQR) at inclusion in the  
adherence program
117 (0–36 150) 1735 (7–118 491) 79 (42–425) 100 (0–36 150) .529
Duration of follow up with EMs during the adherence  
program (days, Q1, Q3)
858 (168, 1957) 191 (75, 1275) 1460 (653, 2445) 1068 (288, 2308) .389
CD4 cell count/μL, median (IQR) at time of neurocognitive 
assessment
603 (486–735) 607 (500–654) 605 (474–735) 601 (498–829) .498
Undetectable patients at time of neurocognitive assessment 48 (81%) 15 (68%) 15 (94%) 18 (85%) .152
Difference between date of neurocognitive assessment and 
start of follow-up in the adherence program (days, Q1, Q3)a
1252 (562, 2195) 587 (373, 1894) 1364 (1116, 2340) 1450 (668, 2105) .206
Duration of treatment (days, Q1, Q3) 3430 (1781, 5655) 2415 (1507, 4348) 2748 (820, 4837) 3511 (2931, 6265) .041
Duration of treatment before EMs start of follow-up (days, 
Q1, Q3)
2124 (21, 4357) 1356 (0, 3283) 796 (25, 2413) 3116 (1898, 4907) .077
Abbreviations: EM, electronic monitor; HAND, human immunodeficiency virus-associated neurocognitive disorders; HIV, human immunodeficiency virus; IQR, interquartile range; NC, 
neurocognitive; RNA, ribonucleic acid.
aFollow up for all patients in the adherence program began before they had their neurocognitive assessments, except for 2 who had their neurocognitive assessments before being fol-
lowed in the adherence program.
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patients, the difference between the 2 measures was resolved by 
identifying NMPs and recalculating adherence accordingly.
Adherence to Combined Antiretroviral Therapy 
As shown in Figure 1, adherence over 3 years of 65 127 daily 
repeated electronic adherence measurements showed a signifi-
cant decrease in adherence after 1 year in the group of patients 
diagnosed with HAND compared with the groups without a 
HAND diagnosis (absence of NCDs and non-HIV-associated 
disorders), for whom adherence remained approximately sta-
ble during the 3 years of follow-up. A GEE model of adherence 
as a function of time (polynomial function), HAND diagnosis 
(absence of NCDs/HIV-associated disorders/non-HIV-asso-
ciated disorders), and their interactions showed a significant 
interaction of HIV-associated disorders with time, ie, a sig-
nificantly different adherence pattern over time for patients 
diagnosed with HAND (the solid blue curve in Figure  1). In 
contrast, adherence in patients without NCDs and patients with 
non-HIV-associated disorders did not vary significantly over 
time (superposition of solid red and green curves in Figure 1).
Variability of the model predictions as assessed by model- 
derived confidence intervals (CIs) (dashed curves in Figure 1) 
was especially large in the case of HIV-associated disorders for 
the second half of follow-up period. Adherence was estimated at 
approximately 85% (CI, 76%–91%) at the beginning of the fol-
low-up for all HAND categories (no significant effect of HAND 
variable at baseline). After 3 years, adherence slightly increased 
to 95% (CI, 85%–98%) in patients without NCDs and patients 
with non-HIV-associated disorders, but it decreased dramati-
cally to approximately 50% (CI, 20%–80%) in HAND patients.
Sensitivity analysis (Supplementary Figure  1) showed a 
slightly lower estimate of adherence as presented in Figure 1. 
The adapted model was similar to that in the principal analysis, 
and the patterns of the curves were similar. Electronic moni-
tors can underestimate adherence rates among individuals who 
remove their pills from EMs with the intention of ingesting 
them later, so-called “pocket-dosing”. Therefore, these data were 
not included in the principal analysis and were only used in the 
sensitivity analysis to compare the results.
Viral Load Over Time
As shown in Figure 2, the probability of having a detectable viral 
load (probability of HIV RNA >20 copies/mL) varied according 
to the neurocognitive group (absence of NCDs, non-HIV-as-
sociated disorders, HIV-associated disorders). Patients with 
HAND showed an increased probability of detectable RNA rel-
ative to the other 2 categories.
DISCUSSION
This study expands on longitudinal adherence patterns to 
cART over a course of 3  years’ time as a function of HAND 
diagnosis. To our knowledge, the current study is the first to 
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Figure 1. Adherence to cART per neurocognitive group over time. Abbreviation: HIV, human immunodeficiency virus.
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demonstrate EMs measured adherence as a function of neu-
rocognitive impairment over a long period of time. Consistent 
with our study hypothesis, patients diagnosed with HAND had 
higher rates of nonadherence and steeper declines in adher-
ence over time and a higher probability of having a detectable 
viral load. Indeed, HAND is typically associated with memory 
impairment that leads to forgetfulness, which represents a chal-
lenge for medication management in daily life [25]. Human 
immunodeficiency virus-associated NCD is also associated 
with impairment in executive functions, psychomotor slowing, 
and attention, all of which have been shown to have a negative 
impact on adherence [18, 26].
Patients with cognitive disorders not related to HIV infection 
exhibited a similar adherence pattern as those without neu-
rocognitive deficits. Non-HIV-related cognitive impairments 
were related to depression, anxiety, alcohol, illicit drug or can-
nabis use, smoking, and illiteracy. It is notable that a number of 
HIV-positive patients suffer from depression and anxiety as a 
consequence of their HIV status [27, 28]. In the context of HIV 
infection, alcohol use, depression, and anxiety are associated 
with a greater risk of nonadherence [29, 30]. Figure 1 shows that 
patients diagnosed with HAND exhibited lower adherence than 
those with NCDs not related to HIV. This shows that the asso-
ciation between HAND and adherence is stronger than non-
HIV-related conditions. Furthermore, patients with adherence 
difficulties, or those initiating cART treatment, are those who 
are referred to the adherence program. Our results show that 
patients with adherence difficulties and no HAND still show 
higher adherence than those who have HANDs.
As similarly reported in previous studies [1], although 
patients diagnosed with HAND did not have any detectable 
viremia at the time of neurocognitive assessment, they nev-
ertheless demonstrated neurocognitive deficits. However, as 
shown in Figure 2, the probability of obtaining detectable viro-
logical rebound was higher in the group with HIV-associated 
disorders than in the groups having non-HIV-associated disor-
ders and those without NCDs.
Strengths and Limitations
Because medication adherence of patients was followed for a 
median of 3.4  years before the date of neurocognitive assess-
ment, which was only cross-sectional in time, we were unable 
to establish a temporal causality between declines in cognition 
and suboptimal adherence. Thus, only an association can be 
proposed. In addition, because NCD testing is not performed 
on a routine basis from HIV baseline diagnoses over time, it 
may be possible that those patients presented with NCDs years 
before the time of neurocognitive assessment. Patients could 
have intentionally or nonintentionally become nonadherent 
and consequently developed neurocognitive problems or, con-
versely, may have developed nonadherence as a consequence of 
their NCDs, especially in the case of prospective memory and 
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Figure 2. Human immunodeficiency virus (HIV) ribonucleic acid (RNA) detectability over time per neurocognitive group.
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attention disorders. Nevertheless, our analysis showed that the 
probability of having a detectable viral load over time (>20 cop-
ies/mL) was higher among the group with HANDs compared to 
the other 2 groups (Figure 2).
Another limitation of our study is the small number of par-
ticipants, which did not allow us to analyze the different pat-
terns of nonadherence according to the severity of the NCDs 
(ANI, MND, and HAD). Despite being asymptomatic, patients 
diagnosed with ANI are clinically relevant because the litera-
ture shows that both symptomatic and asymptomatic NCDs 
are associated with lower adherence, lower quality of life, and 
unemployment [31]. In addition, patients with ANI can tran-
sition to more severe forms of HAND [32]. However, despite 
the small sample size, we were able to show significant patterns 
of adherence among the 3 groups (HANDs, non-HAND, and 
absence of NCDs). This represents a valuable combination of 
data collected prospectively by the SHCS, a medication adher-
ence program in which EMs are used routinely in care in addi-
tion to standardized neurocognitive assessments. Moreover, 
we analyzed daily electronic measurements of adherence over 
the entire duration of follow up, with a median of 858  days 
(2.3  years); thus, although the analysis was performed in 59 
patients, the data representing daily measurements provided 
in-depth daily and continuous representations of patient behav-
ior over an extended period of time. This allowed us to demon-
strate the exact long-term patterns of chronic medication intake 
among HIV-positive patients instead of a summary of adher-
ence measurements or self-reported adherence, which can 
introduce bias. In conclusion, there appears to be an association 
between HAND and medication adherence. Further research 
with several neurocognitive tests performed over time, along 
with medication adherence monitoring with EMs, is needed 
to further investigate the evolution of adherence over time as a 
function of the presence or absence of NCDs.
CONCLUSIONS
Our results indicate that the detection of a NCD should raise 
concern that the patient may be at higher risk of viral load 
detection and virologic failure. Furthermore, for patients pre-
senting an increase in viral load, assessing their cognitive 
function could be appropriate if the decrease in adherence is 
nonintentional and linked to cognitive disorders. To date, 
the most successful interventions for preventing, delaying, or 
improving HAND include early initiation of and adherence 
to cART [33]. Therefore, developing effective strategies to 
enhance medication adherence in these patients is crucial. The 
key to developing effective strategies is knowledge of a patient’s 
pattern of drug-taking behavior, and analyses of EMs data can 
provide this information. Combining drug-taking behavior 
with patients’ daily routines (eg, with meals or at bedtime) or 
relying on support from significant others and inviting them 
to a medication adherence support program are good examples 
of strategies that could be developed to help patients diagnosed 
with HAND overcome their nonadherence.
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